The Value of Novel Thrombus Markers in the Diagnosis and Treatment of Acute Pulmonary Embolism

Launched by BEIJING ANZHEN HOSPITAL · Mar 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new method to help diagnose and treat a serious condition called acute pulmonary embolism (APE), which occurs when a blood clot blocks blood flow to the lungs. The researchers want to see if a new set of blood markers can help doctors detect APE earlier and monitor how well patients are responding to treatment. They aim to include 200 patients who are newly diagnosed with APE and haven't received any blood-thinning treatments in the past month.

To be eligible for the trial, participants must be at least 18 years old and have been diagnosed with APE using a specific imaging test. However, individuals with other serious health conditions or a history of certain diseases may not be able to participate. If someone joins the trial, they can expect to provide blood samples at different times before and after their treatment. The goal is to improve how APE is diagnosed and treated, ultimately reducing the chances of serious complications and improving quality of life for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1.Patients diagnosed with APE for the first time through CTPA in clinical practice and who have not received anticoagulant therapy in the past month; 2.Age ≥ 18 years old.
• Exclusion Criteria:
• • 1. Complicated with other thrombotic diseases, complicated with important organ damage such as heart, liver, kidney, and previous history of pulmonary embolism; 2. Malignant tumors; 3. Renal dialysis patients; 4. Antiphospholipid syndrome; 5. Immune system diseases; 6. Hematological diseases; 7. DIC caused by severe infection; 8. Patients judged by clinicians to be unfit for clinical practice.